Parameswaran Venugopal to Rituximab
This is a "connection" page, showing publications Parameswaran Venugopal has written about Rituximab.
Connection Strength
0.971
-
Phase 1 study of lenalidomide plus dose-adjusted EPOCH-R in patients with aggressive B-cell lymphomas with deregulated MYC and BCL2. Cancer. 2019 06 01; 125(11):1830-1836.
Score: 0.163
-
Bendamustine and Rituximab: Complete Response in a 62-Year-Old Female with an Aggressive Lymphoma and an Ejection Fraction of 20. Chemotherapy. 2017; 62(2):140-146.
Score: 0.141
-
Granulocyte-macrophage colony stimulating factor-induced immune priming of cyclophosphamide, doxorubicin, vincristine, and prednisone with rituximab chemoimmunotherapy in previously untreated patients with diffuse large B-cell lymphoma and mantle cell lymphoma. Leuk Lymphoma. 2011 Nov; 52(11):2097-104.
Score: 0.096
-
Efficacy and safety of clofarabine in relapsed and/or refractory non-Hodgkin lymphoma, including rituximab-refractory patients. Cancer. 2011 Apr 01; 117(7):1490-7.
Score: 0.092
-
Recurrent thrombotic thrombocytopenic purpura treated repeatedly and successfully with the monoclonal antibody rituximab. Clin Adv Hematol Oncol. 2006 Mar; 4(3):215-7; discussion 217-8.
Score: 0.067
-
Relapsed non-Hodgkin lymphoma in fraternal twins managed successfully with rituximab maintenance therapy. Clin Adv Hematol Oncol. 2005 Feb; 3(2):136-9; discussion 139-40.
Score: 0.062
-
Lymphomatoid granulomatosis treated with rituximab and chemotherapy. Clin Adv Hematol Oncol. 2003 Nov; 1(11):658-60; discussion 660.
Score: 0.057
-
Older patients with primary central nervous system lymphoma: Survival and prognostication across 20 U.S. cancer centers. Am J Hematol. 2023 06; 98(6):900-912.
Score: 0.055
-
HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis. Blood Adv. 2021 07 27; 5(14):2852-2862.
Score: 0.049
-
Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multicenter cohort study. Haematologica. 2021 07 01; 106(7):1932-1942.
Score: 0.048
-
Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2017 Nov 01; 35(31):3538-3546.
Score: 0.037
-
Long-term remission of paroxysmal nocturnal hemoglobinuria following chemoimmunotherapy for non-Hodgkin lymphoma. Clin Adv Hematol Oncol. 2012 Feb; 10(2):134-6.
Score: 0.025
-
Safety and efficacy of combination therapy with fludarabine, mitoxantrone, and rituximab followed by yttrium-90 ibritumomab tiuxetan and maintenance rituximab as front-line therapy for patients with follicular or marginal zone lymphoma. Clin Lymphoma Myeloma Leuk. 2011 Dec; 11(6):467-74.
Score: 0.024
-
GM-CSF plus rituximab immunotherapy: translation of biologic mechanisms into therapy for indolent B-cell lymphomas. Leuk Lymphoma. 2008 Sep; 49(9):1681-92.
Score: 0.020
-
Efficacy and safety of rituximab combined with ESHAP chemotherapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. Clin Lymphoma Myeloma. 2007 May; 7(6):406-12.
Score: 0.018
-
Durable remission of intravascular lymphoma with central nervous system involvement following chemotherapy and rituximab. Clin Adv Hematol Oncol. 2006 Jun; 4(6):439-41.
Score: 0.017